Skip to main content

Table 1 Baseline characteristics and clinical outcomes stratified by median NLR value

From: Neutrophil-to-lymphocyte ratio as a predictive biomarker for moderate-severe ARDS in severe COVID-19 patients

Baseline characteristicsNon-ARDSN = 37ARDSN = 44Pvalues
 Age49 (36.5–62.5)53.5(43–70.5)0.110
 Gender/case (%)  0.891
  Male23 (62.3%)28 (63.6%)
  Female14 (37.8%)16 (36.4%)
 BMI (kg/m2)23.05 (22.00–27.25)24.78(21.29–27.41)0.816
 Smoking/case (%)1 (2.7%)2 (4.5%)1.000
 Comorbidities/case (%)
  Diabetes3 (8.1%)15 (34.15)0.007
  Hypertension7 (18.9%)8 (18.2%)0.932
  Chronic pulmonary disease2 (5.4%)9 (20.5%)0.049
  Cardiovascular disease2 (5.4%)2 (4.5%)1.000
  Cerebrovascular disease0 (0%)3 (6.8%)0.246
  Renal disease1 (2.7%)2 (4.5%)1.000
  Liver disease2 (5.4%)2 (4.5%)1.000
 Vital signs
  MAP/mmHg94.67 (89.17–100.50)97.83(91.75,108.84)0.162
  Heart rate (beats/min)88 (77.5–99)92.5 (85.25–104)0.175
  Respiratory rate (breaths/min)20 (20–22.5)21 (20–23)0.107
  Pulse oxygen saturation/%96 (93.75–97.25)95 (90.25–97)0.486
 Laboratory findings
  WBC/109/L5.43 (4.05–6.59)6.47 (3.94–9.62)0.122
  Hemoglobin/g/L141 (127–153.5)132 (117.25–146.5)0.107
  Total bilirubin (μmol/L)9 (5.93–15.6)9.3 (6.65–14.3)0.927
  AST (IU/L)30.5 (19–39.75)29.15 (15.75–57.68)0.764
  ALT (IU/L)30 (25–39.8)35 (25.75–51.6)0.221
  Creatinine (μmol/L)71.75 (54.35–79.75)69.2 (54.63–80.53)0.980
  PT/s12.7 (12.5–13.98)13.1 (12.6–13.8)0.787
  APTT/s32.75 (29.1–40.13)31.3 (28.8–35.5)0.246
  NLR/%6.4 (3.75–13.1)13.55 (6.05–24.13)0.002
Clinical outcomesLow NLRN = 41High NLRN = 40Pvalue
 Respiratory support
  High-flow nasal cannula15 (36.6%)16 (40%)0.752
  Noninvasive ventilation5 (12.2%)17 (42.5%)0.002
  Invasive ventilation2 (4.9%)8 (20%)0.048
 ARDS
  Mild-moderate ARDS11 (26.8%)11 (27.5%)0.946
  Moderate-severe ARDS5 (12.2%)11 (42.5%)0.002
  1. Data are presented as interquartile range or number (percentage)
  2. BMI body mass index, MAP mean arterial pressure, WBC white blood cell, AST aspartate aminotransferase, ALT alanine aminotransferase, PT prothrombin time, APTT activated partial thromboplastin time, NLR neutrophil-to-lymphocyte ratio, ARDS acute respiratory distress syndrome